Adakveo

RSS

Revoked

This medicine's authorisation has been revoked

crizanlizumab
MedicineHumanRevoked

Irish is available via eTranslation, the European Commission's machine translation service.

Translate to Irish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

The marketing authorisation for Adakveo has been revoked by the European Commission.

български (BG) (258.53 KB - PDF)

Amharc

español (ES) (196.57 KB - PDF)

Amharc

čeština (CS) (232.71 KB - PDF)

Amharc

dansk (DA) (192.47 KB - PDF)

Amharc

Deutsch (DE) (201.08 KB - PDF)

Amharc

eesti (ET) (172.19 KB - PDF)

Amharc

ελληνικά (EL) (256.85 KB - PDF)

Amharc

français (FR) (197.58 KB - PDF)

Amharc

hrvatski (HR) (222.55 KB - PDF)

Amharc

italiano (IT) (193.4 KB - PDF)

Amharc

latviešu (LV) (236.29 KB - PDF)

Amharc

lietuvių (LT) (231.44 KB - PDF)

Amharc

magyar (HU) (226.21 KB - PDF)

Amharc

Malti (MT) (238.09 KB - PDF)

Amharc

Nederlands (NL) (195.9 KB - PDF)

Amharc

polski (PL) (233.87 KB - PDF)

Amharc

português (PT) (198.01 KB - PDF)

Amharc

română (RO) (232.25 KB - PDF)

Amharc

slovenčina (SK) (227.5 KB - PDF)

Amharc

slovenščina (SL) (228.97 KB - PDF)

Amharc

suomi (FI) (187.61 KB - PDF)

Amharc

svenska (SV) (192.38 KB - PDF)

Amharc

Product information

български (BG) (1.59 MB - PDF)

Amharc

español (ES) (1.48 MB - PDF)

Amharc

čeština (CS) (1.85 MB - PDF)

Amharc

dansk (DA) (1.35 MB - PDF)

Amharc

Deutsch (DE) (1.4 MB - PDF)

Amharc

eesti (ET) (1.3 MB - PDF)

Amharc

ελληνικά (EL) (4.58 MB - PDF)

Amharc

français (FR) (1.47 MB - PDF)

Amharc

hrvatski (HR) (1.82 MB - PDF)

Amharc

italiano (IT) (1.92 MB - PDF)

Amharc

latviešu (LV) (1.36 MB - PDF)

Amharc

lietuvių (LT) (1.46 MB - PDF)

Amharc

magyar (HU) (1.47 MB - PDF)

Amharc

Malti (MT) (1.77 MB - PDF)

Amharc

Nederlands (NL) (1.3 MB - PDF)

Amharc

polski (PL) (1.66 MB - PDF)

Amharc

português (PT) (1.57 MB - PDF)

Amharc

română (RO) (1.81 MB - PDF)

Amharc

slovenčina (SK) (1.67 MB - PDF)

Amharc

slovenščina (SL) (1.58 MB - PDF)

Amharc

suomi (FI) (1.3 MB - PDF)

Amharc

svenska (SV) (1.42 MB - PDF)

Amharc

Íslenska (IS) (1.58 MB - PDF)

Amharc

norsk (NO) (1.49 MB - PDF)

Amharc
Latest procedure affecting product information:004874/A20/0013
03/08/2023
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (130.35 KB - PDF)

Amharc

español (ES) (118.8 KB - PDF)

Amharc

čeština (CS) (122.23 KB - PDF)

Amharc

dansk (DA) (119.44 KB - PDF)

Amharc

Deutsch (DE) (120.75 KB - PDF)

Amharc

eesti (ET) (114.35 KB - PDF)

Amharc

ελληνικά (EL) (126.63 KB - PDF)

Amharc

français (FR) (118.57 KB - PDF)

Amharc

hrvatski (HR) (120.92 KB - PDF)

Amharc

italiano (IT) (120.25 KB - PDF)

Amharc

latviešu (LV) (122.37 KB - PDF)

Amharc

lietuvių (LT) (120.31 KB - PDF)

Amharc

magyar (HU) (120.09 KB - PDF)

Amharc

Malti (MT) (124.49 KB - PDF)

Amharc

Nederlands (NL) (117.21 KB - PDF)

Amharc

polski (PL) (122.47 KB - PDF)

Amharc

português (PT) (119.5 KB - PDF)

Amharc

română (RO) (121.18 KB - PDF)

Amharc

slovenčina (SK) (122.07 KB - PDF)

Amharc

slovenščina (SL) (117.66 KB - PDF)

Amharc

suomi (FI) (115.45 KB - PDF)

Amharc

svenska (SV) (116.27 KB - PDF)

Amharc

Íslenska (IS) (116.95 KB - PDF)

Amharc

norsk (NO) (121.81 KB - PDF)

Amharc

Product details

Name of medicine
Adakveo
Active substance
Crizanlizumab
International non-proprietary name (INN) or common name
crizanlizumab
Therapeutic area (MeSH)
Anemia, Sickle Cell
Anatomical therapeutic chemical (ATC) code
B06AX01

Pharmacotherapeutic group

Other hematological agents

Therapeutic indication

Adakveo is indicated for the prevention of recurrent vaso occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older.

It can be given as an add on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.

Authorisation details

EMA product number
EMEA/H/C/004874

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation.

Marketing authorisation holder
Novartis Europharm Limited

Vista Building
Elm Park
Merrion Road
Dublin 4
Ireland

Opinion adopted
23/07/2020
Marketing authorisation issued
28/10/2020
Revocation of marketing authorisation
03/08/2023
Revision
6

Assessment history

български (BG) (230.15 KB - PDF)

Amharc

español (ES) (181.21 KB - PDF)

Amharc

čeština (CS) (227.16 KB - PDF)

Amharc

dansk (DA) (188.81 KB - PDF)

Amharc

Deutsch (DE) (220.44 KB - PDF)

Amharc

eesti (ET) (162.9 KB - PDF)

Amharc

ελληνικά (EL) (244.66 KB - PDF)

Amharc

français (FR) (207.95 KB - PDF)

Amharc

hrvatski (HR) (208.58 KB - PDF)

Amharc

italiano (IT) (200.27 KB - PDF)

Amharc

latviešu (LV) (225.08 KB - PDF)

Amharc

lietuvių (LT) (200.49 KB - PDF)

Amharc

magyar (HU) (202.69 KB - PDF)

Amharc

Malti (MT) (297.5 KB - PDF)

Amharc

Nederlands (NL) (200.26 KB - PDF)

Amharc

polski (PL) (214.25 KB - PDF)

Amharc

português (PT) (193.71 KB - PDF)

Amharc

română (RO) (204.32 KB - PDF)

Amharc

slovenčina (SK) (211.08 KB - PDF)

Amharc

slovenščina (SL) (201.8 KB - PDF)

Amharc

suomi (FI) (176.13 KB - PDF)

Amharc

svenska (SV) (187.77 KB - PDF)

Amharc

This page was last updated on

Share this page